In summary, our current results suggest that FAK inhibitors suppress Dasatinib induced FAK activation, and combined treatment with Dasatinib and FAK inhibitors may represent a novel therapeutic strategy for HCC. This evidence concerns the gene PTK2 and hepatocellular carcinoma.